EVALUATION OF POSTNATAL PATHOGENETIC FACTORS INFLUENCING THE COURSE AND TREATMENT OUTCOMES OF THRESHOLD-STAGE AND AGGRESSIVE POSTERIOR RETINOPATHY OF PREMATURITY
Objective: To evaluate postnatal pathogenetic factors influencing the clinical course and treatment outcomes of the active phase of retinopathy of prematurity (ROP), and to assess their relationship with specific management strategies. Methods: A retrospective analysis was conducted on the medical records of 88 patients (176 eyes) diagnosed with threshold-stage ROP or aggressive posterior ROP (AP-ROP). All patients met the same inclusion criteria: gestational age (GA) at birth of less than 32 weeks, birth weight under 1,500 g, and disease progression leading to threshold-stage ROP. Depending on the management strategy utilized, patients were divided into four groups: • Group 1: 23 children (26%) who received intravitreal injections of ranibizumab. • Group 2: 23 children (26%) who received intravitreal injections of aflibercept. • Group 3: 22 children (25%) who underwent retinal laser photocoagulation. • Group 4: 19 children (22%) who required combination therapy (anti-VEGF + laser photocoagulation and/or surgery). Results: The most unfavorable clinical course was observed in the combination therapy group, which showed a statistically significant (p=0.01) prevalence of anemia, intraventricular hemorrhage (IVH), and neonatal seizures. This group also had a longer duration of high-frequency oscillatory ventilation, along with more frequent platelet transfusions and erythropoietin (EPO) injections. In the laser photocoagulation group, most patients had threshold stage II disease (38%), whereas only 4% of the aflibercept group had this stage. In children receiving anti-VEGF monotherapy, the average duration of mechanical ventilation was 55 days, which was comparable to that of the combination therapy group. Conclusion: Postnatal pathogenetic factors including anemia, IVH, neonatal seizures, prolonged respiratory support, and the subsequent need for blood product transfusions and EPO therapy may actively drive ROP progression and adversely affect treatment outcomes. Early identification and clinical optimization of these systemic factors may improve the prediction of disease severity and help guide targeted treatment choices. Keywords: Retinopathy of prematurity, active phase, threshold-stage ROP, risk factors for progression, prognostic factors, aggressive posterior retinopathy of prematurity
Сведения
- Журнал
- Avicenna Bulletin
- Опубликовано
- 2026 · Т. 28, № 3, С. 664-674
- Язык
- Английский
- ISSN
- 2074-0581 · 2959-6327
- Издатель
- Avicenna Tajik State Medical University
- Аффилиации
- Russian Children's Clinical Hospital – branch of the N.I. Pirogov Russian National Research Medical University, Moscow, Russian Federation
N.I. Pirogov Russian National Research Medical University, Moscow, Russian Federation
International Scientific and Practical Center for Tissue Proliferation, Moscow, Russian Federation